Bob Lederer PRVR

Google Genomics. Watson & genetics. Pharmacos: PROs, personalized med (PRVR 11.17.14)

To subscribe to PRVR and receive an email with multiple links to the latest video report, please click: http://ow.ly/Clawn

Pharma Research VIDEO Report, a co-partnered production with the Pharmaceutical Marketing Research Group, is sponsored this week by the Toluna Healthcare Practice, offering highly engaged physicians, health professionals and ailment sufferers for global research using cutting-edge methodologies, sophisticated, yet easy-to-use analytic tools and specialized products including Pharmacy Intercept, dedicated communities, patient record studies and more.

Find out about the Toluna Healthcare Practice at its homepage: http://www.toluna-group.com/about-toluna/industries-we-serve/healthcare/overview
On this PRVR:

1) Google Genomics plans to store individuals’ genomes in the cloud, where they can be analyzed en masse by healthcare researchers.
Link: http://bigthink.com/ideafeed/for-new-era-of-personalized-medicine-google-to-store-individual-genomes-in-the-cloud

2) The IBM Watson program has invested in Pathway Genomics, which will use Watson’s computing prowess to offer a consumer app that can provide answers to personal health questions.
Link: http://www.thestreet.com/story/12950769/1/how-ibm-and-watson-plan-to-use-your-genetic-code-to-help-you-live-longer.html

3) Except for Jannsen, Novartis and Roche, few of the top 12 pharmaceutical companies are commercially ready for a personalized medicine business model
Link: http://www.diaceutics.com/new-report-reveals-most-leading-pharma-companies-still-not-commercially-ready-personalized-medicine

4) Patient Reported Outcomes (PROs) are of interest to pharmaceutical companies in their marketing strategies, but they are not finding buy-in from regulatory agencies.
LInk: http://www.marketwired.com/press-release/drug-makers-report-average-22-patient-reported-outcomes-endpoints-appear-on-final-product-1966590.htm

5) Sentrian’s remote patient intelligence platform plans to spot individuals’ impending health problems before they require hospitalization.
Link: http://www.prnewswire.com/news-releases/sentrian-the-worlds-first-remote-patient-intelligence-company-launches-to-eliminate-preventable-hospitalization-282122331.html

Bob Lederer RFL Communications, Inc.

Med cost up 3-5%; pharmacos cut MD speaker fees; FDA eases adverse event reporting (PRVR–3/10/14)

This week’s Pharma Research VIDEO Report: 1) Costs for medications will rise 3-5% this year, after having dramatically slowed in recent years. 2) Pharmaceutical companies have radically reduced what they pay doctors to speak, well at least many of them have. 3) Generic drug manufacturers will fight FDA proposals that they be required to update their product labels when new information with concerns about branded equivalents appear. 4) FDA will make availability of adverse event reports much easier to find and collect. 5) Health care providers say the Affordable Care Act needs changes and revisions, but overwhelmingly see it as a positive step for U.S. healthcare. 6) The multimillion dollar injectable drug market for chronic conditions like diabetes may be in or a shakeup if Mir Imran’s “Robotic Pill” gets FDA approval. It is in preclinical testing. 7) Media technology company Sticky wins the PM360 award for most innovative company. 8) A press release last week declared the first broadcast medical marijuana commercial. The release pointed to Comcast as the broadcaster. Since the taping of this video, PRVR has learned that this release was part of a misleading campaign. We apologize for this mistaken report.

Here is the link to the commercial:
https://www.marijuanadoctors.com/content/page/view/91

Bob Lederer RFL Communications, Inc.

Comparing Observational MR; Proposed Part D changes; FDA generic Rx initiative; HIMSS reports on HC mobile implementation vs. usage; MDLinx verifying European MDs; Novartis expands clinical data transparency; SAP testing “Medical Insights” cancer patient assistance (PMRVR–3/4/14)

In this Pharma Market Research VIDEO Report:  1) GRACE, an 11-item checklist of data and methods, allows testing of baseline quality criteria for observational research.  2) The CMS is proposing changes to Medicare Part D. The big picture change calls for stopping automatic Medicare coverage of two drug classes; the underlying consideration in the plan could lead to federal government price negotiations with pharmacos (expressly forbidden in legislation that established Part D).  3) The FDA launches a $20 million initiative to test generic drug production, which represents 80% of Rx drugs. India, wiht its $15 billion in annual generic drug production, is a primary focus but China is also in the crosshairs. 4) HIMSS mobile research study investigates its implementation and use by healthcare providers.  5) GfK reports an upsurge in 2013 in purchase of mobile-connected medical devices in top European countries.  6) MDLinx is launching its physician verification service in Europe.  7) The Kaiser Family Foundation reports users of the ACA website were more price-oriented than physician-focused.  8) Novartis says it has extended its pharmaco leadership in clinical trial data transparency.  9) SAP is testing “Medical Insights,” a capability that aids cancer patients by pulling relevant data from many cancer data sources, runs advanced analytics and delivers customized results in real time.